3Helix has developed a series of proprietary collagen hybridizing peptides that directly target the damaged collagen molecule. Collagen is the major component of nearly every human tissue, with an essential role in supporting cell growth and tissue formation. Damage to collagen is a strong indication of connective tissue injury, as well as a variety of diseases involving inflammation and abnormal tissue remodeling, such as cancer, myocardial infarction, arthritis, osteoporosis, and fibrosis. However, targeting damaged collagen is difficult with conventional technologies. In addition to providing CHP as a research tool for laboratory use in academia and industry, 3Helix is advancing its compounds to enable new pathways to achieving diagnostic and therapeutic objectives.

3Helix is based in Salt Lake City, Utah. It was founded by Drs. Yang Li and Michael Yu based on the technology that they invented at the Johns Hopkins University.


Founder Prof. Michael Yu describes examples of the vast potential medical applications of CHP, which was previously termed collagen mimetic peptide. (No access to Youtube? Watch the videohere.)